Welcome to our dedicated page for CG Oncology SEC filings (Ticker: CGON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CG Oncology, Inc. filings document the public-company record of a late-stage clinical biopharmaceutical issuer focused on cretostimogene grenadenorepvec for non-muscle invasive bladder cancer. Recent Form 8-K reports disclose financial results, Regulation FD materials, clinical-program updates, FDA-related communications, executive appointments, board changes and other material events.
The company's SEC record also includes proxy disclosures on board structure, compensation and stockholder matters, along with registration and prospectus materials related to common-stock offerings under an open market sale agreement. These filings describe CG Oncology's Nasdaq-listed common stock, capital-raising activity, governance framework, clinical development priorities and risk-related disclosure context.
CG Oncology, Inc. reported consolidated cash, cash equivalents and marketable securities of approximately $661.1 million and working capital of approximately $642.6 million, giving the company an explicit runway the company says extends into the first half of 2028. The company recorded a net loss of $75.9 million for the six months ended June 30, 2025, compared with a $35.8 million loss in the prior-year period, driven by higher research and development spending of $58.8 million and increased general and administrative costs of $32.2 million during the six months.
The balance sheet shows marketable securities of $646.4 million and a $26.0 million note receivable. Significant corporate developments disclosed include an Open Market Sale Agreement for up to $250.0 million (no sales as of June 30, 2025), a July 20, 2025 conversion and consolidation of an SPV, and a July 29, 2025 jury verdict unanimously rejecting ANI Pharmaceuticals' unjust enrichment claims so no royalty or damages are due under the disputed agreement.
CG Oncology, Inc. filed a current report to note that it issued a press release on August 8, 2025 announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1, meaning it is provided for informational purposes and is not treated as filed for liability purposes under the Exchange Act. The company’s common stock continues to trade on the Nasdaq Global Select Market under the symbol CGON.